Quantum Genomics Société Anonyme

DB:2QG Stock Report

Market Cap: €5.0m

Quantum Genomics Société Anonyme Past Earnings Performance

Past criteria checks 0/6

Quantum Genomics Société Anonyme's earnings have been declining at an average annual rate of -2.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 9.9% per year.

Key information

-2.2%

Earnings growth rate

6.0%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-9.9%
Return on equityn/a
Net Margin-49,478,810.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Quantum Genomics Société Anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2QG Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-910
31 Mar 240-610
31 Dec 230-320
30 Sep 230-1120
30 Jun 230-1830
31 Mar 231-2230
31 Dec 223-2530
30 Sep 223-2220
30 Jun 225-2030
31 Mar 225-1940
31 Dec 216-1740
30 Sep 217-1850
30 Jun 218-1850
31 Mar 216-1750
31 Dec 204-1640
30 Sep 204-1440
30 Jun 200-1020
31 Mar 200-1030
31 Dec 192-1040
30 Sep 190-930
30 Jun 190-1030
31 Mar 190-1130
31 Dec 180-1220
30 Sep 180-1220
30 Jun 180-1220
31 Mar 180-1020
31 Dec 170-920
30 Sep 170-820
30 Jun 170-720
31 Mar 170-620
31 Dec 160-520
30 Sep 160-520
30 Jun 160-520
31 Mar 160-420
31 Dec 150-420
30 Sep 150-310
30 Jun 150-310
31 Mar 150-210
31 Dec 140-210
30 Sep 140-210
30 Jun 140-210
31 Mar 140-210
31 Dec 130-210

Quality Earnings: 2QG is currently unprofitable.

Growing Profit Margin: 2QG is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2QG is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare 2QG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2QG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 2QG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies